Medical Oncologist
Treatment resistance
When Lenvatinib Stops Working: — Resistance and What Comes Next
If your latest scan shows the cancer growing again while you are on lenvatinib, that is called progression. It means the drug's period of control has ended — and the next decision, what to do now, is the one that matters most.
Medically reviewed by Dr. T. Raghavender Reddy, Medical Oncologist, MBBS · DM (Medical Oncology) · MD (Radiation Oncology) · Last reviewed August 2026
- Resistance is built into how cancer works — Most targeted therapies control cancer for a period before the tumour adapts. This is expected, not a sign anything went wrong.
- Retesting can find new options — A biopsy or blood test after progression may reveal new tumour changes your team can target with a different treatment.
- Second-line treatments exist — For the cancers lenvatinib treats most — thyroid, liver, endometrial — established second-line options are recognised in international guidelines.
- Clinical trials belong in this conversation — Trials may offer access to treatments not yet approved in India. They are an equal option, not a last resort.
17+
Cancer Specialists
on Panel
on Panel
96.9%
Breast Cancer
Survival Rate*
Survival Rate*
15,000+
Patients
Treated
Treated
4.8★
Google Rating
(800+ reviews)
(800+ reviews)
Lenvatinib works by blocking signals that help tumours build their own blood supply. Over time, cancer cells find alternative signalling pathways and grow around those blocks. When that happens, your team will reassess your scans, consider retesting the tumour, and recommend the next treatment based on your cancer type and what options remain available.
Why does lenvatinib stop working?
Lenvatinib targets several proteins — including VEGFR, FGFR, and PDGFRα — that tumours use to build new blood vessels and sustain rapid growth. It does not kill cancer cells directly. It starves them of the growth signals they depend on.
Primary resistance means the cancer never responded. The tumour had alternative survival routes before treatment started, so blocking those particular proteins made little difference from the beginning.
Acquired resistance is more common. The cancer initially responds, then finds a different signalling pathway — often through a receptor family lenvatinib does not cover — and uses that to grow again. This is a fundamental property of cancer biology, not a sign that treatment was given incorrectly or that you did anything wrong.
Both types of resistance mark the expected end of a period of disease control. Progression on lenvatinib is a clinical event your team plans for, not a crisis without options.
What happens after progression is confirmed?
Progression is confirmed on imaging
Your oncologist compares the latest scan to the previous one and formally confirms the cancer has grown or spread. This is the trigger for reconsidering the treatment plan.
Your overall fitness is assessed
Before recommending what comes next, your team looks at how you are feeling, your organ function, and how much the progression has changed your situation. These factors shape which options are realistic.
Repeat molecular testing is considered
Tumours accumulate new changes as they adapt to treatment. A repeat biopsy of tissue, or a liquid biopsy from a blood sample, may reveal new mutations or targets that were not present at the time of your original diagnosis.
Second-line options are mapped out
Your oncologist reviews available next treatments against your cancer type, your biopsy results, and your fitness. This conversation should include clinical trials as well as approved second-line treatments.
A plan is agreed and started
Once you and your team agree on the next step, treatment is arranged. At CION, subsequent lines of systemic therapy are given as day care where the schedule allows.
Meet the Specialists
17+ senior cancer specialists. One panel for your case.
Trained at AIIMS, Tata Memorial, and leading international centres. Combined 150+ years of experience. Every complex case is reviewed by 3+ of them — together.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Surgical Oncologist
Surgical Oncologist
Dr. Vinay Mamidala
MBBS, MS(General Surgery), M.Ch(Surgical Oncology), FMAS, FARIS(Ongoing)
Surgical Oncologist
Radiation Oncologist
Radiation Oncologist
Radiation Oncologist
Hematologist
Interventional Radiologist
Dr. Mohammed Imran
Surgical Oncologist
Dr. Vajja Sandeep Kumar
MBBS, MS (General Surgery), DrNB (Surgical Oncology), FALS Oncology
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Get a straight answer from a specialist
45 minutes, your reports reviewed, your questions answered in plain language.
What do the words your oncologist is using mean?
- Progression
- A formal imaging term meaning the cancer has grown by a defined amount or spread to a new site since the last scan. It is the clinical trigger for changing treatment — not a general statement about how you feel day to day.
- Primary resistance
- When the cancer does not respond to a treatment from the very first assessment. The tumour had alternative survival routes from the beginning, before the drug was started.
- Acquired resistance
- When the cancer initially responds but later starts growing again. The tumour has adapted over months by switching on a signalling pathway the drug does not block.
- Bypass pathway
- An alternative molecular route a tumour uses when its usual signalling is blocked. The cancer finds a detour around the block lenvatinib created, using a different set of proteins to sustain growth.
- Liquid biopsy
- A blood test that detects small amounts of tumour DNA circulating in the bloodstream. It can sometimes identify resistance mutations without a surgical or needle biopsy of the tumour itself.
- Second-line treatment
- The next treatment given after the first has stopped working. For each of the cancers lenvatinib is used in, at least one established second-line option is recognised in international guidelines.
What are the treatment options after lenvatinib?
The answer depends on which cancer lenvatinib was treating. There is no single second-line path that applies across all its uses.
For differentiated thyroid cancer, NCCN and ESMO both recognise other kinase inhibitors as established second-line options. If molecular testing reveals a RET mutation or RET fusion, a RET-specific inhibitor may also be appropriate — which is one practical reason to retest at progression rather than assuming the original profile still applies.
For hepatocellular carcinoma, NCCN and ESMO list regorafenib, cabozantinib, and ramucirumab as options in appropriately selected patients. Immunotherapy combinations are also discussed where they were not part of the first-line plan.
For endometrial cancer, the path after lenvatinib depends partly on whether pembrolizumab was given alongside it. Your team will map the options against what your current tumour shows and what you have already received.
Clinical trials belong in this conversation as an equal option. A trial may offer access to a drug or combination not yet approved in India that your molecular profile makes you eligible for. Ask your oncologist to check what is currently open.
Tell your team everything you are taking — including supplements and Ayurvedic or herbal preparations. Some interact with second-line kinase inhibitors in ways that affect how those drugs work, and your team cannot account for an interaction they do not know about.
Explore 100 more Gastrointestinal & Liver Targeted Medicines topics
Drug Deep Dive: Lenvatinib (Lenvima)
- Blood Pressure Spikes on Lenvatinib: The Critical First Two Weeks
- Diarrhoea, Appetite Loss and Rapid Weight Drop on Lenvatinib
- Diet and Nutrition While on Lenvatinib
- Dose Reductions on Lenvatinib: Why Most Patients Need One
- Drug, Food and Supplement Interactions With Lenvatinib
- Fertility, Pregnancy and Contraception on Lenvatinib
- Hand-Foot Skin Reaction on Lenvatinib: Prevention and Relief
- How Does Lenvatinib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Lenvatinib Take to Work?
- How Long Will You Stay on Lenvatinib?
- Lenvatinib (Lenvima, Lenvanix): The Complete Patient Guide
- Lenvatinib Myths: Side Effects, Dose Cuts and 'Giving Up'
- Lenvatinib Price in India: Brand, Generic and Monthly Cost
- Lenvatinib Side Effects: The Complete List and Timeline
- Lenvatinib Success Rate and Survival: An Honest Look at the Numbers
- Lenvatinib With Immunotherapy: The Combination Explained
- Lenvatinib for Radioactive-Iodine-Refractory Thyroid Cancer
- Lenvatinib in Elderly Patients and Those With Other Illnesses
- Lenvatinib vs Sorafenib for Liver Cancer: Which Comes First?
- Taking Lenvatinib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Lenvatinib
- When Lenvatinib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Lenvatinib? Liver, Thyroid, Kidney and Endometrial Cancer
- Will Insurance or a Government Scheme Pay for Lenvatinib?
- Work, Travel and Daily Life on Lenvatinib
Drug Deep Dive: Bevacizumab (Avastin)
- Avastin vs Biosimilar Bevacizumab in India: Cost and Safety
- Bevacizumab (Avastin and biosimilars): The Complete Patient Guide
- Bevacizumab Infusion Day: Premedication, Duration and What to Expect
- Bevacizumab Myths: 'It Dissolves Tumours' and Other Misconceptions
- Bevacizumab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Bevacizumab Side Effects: The Complete List and Timeline
- Bevacizumab Success Rate and Survival: An Honest Look at the Numbers
- Bevacizumab With Chemotherapy: Which Combinations and Why
- Bevacizumab in Elderly Patients and Those With Other Illnesses
- Bevacizumab in Eye Disease vs Cancer: Same Drug, Very Different Dose
- Bleeding, Bowel Perforation and Wound Healing Risks on Bevacizumab
- Diet and Nutrition While on Bevacizumab
- Drug, Food and Supplement Interactions With Bevacizumab
- Fertility, Pregnancy and Contraception on Bevacizumab
- High Blood Pressure on Bevacizumab: Monitoring and Treatment
- How Does Bevacizumab Work? The Anti-VEGF Angiogenesis Inhibitor Explained
- How Long Does Bevacizumab Take to Work?
- How Long Will You Stay on Bevacizumab?
- Protein in Your Urine on Bevacizumab: What the Report Means
- Surgery While on Bevacizumab: The 28-Day Rule
- Tests and Monitoring While You Are on Bevacizumab
- When Bevacizumab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Bevacizumab? Colorectal, Lung, Ovarian, Cervical and Brain Cancer
- Will Insurance or a Government Scheme Pay for Bevacizumab?
- Work, Travel and Daily Life on Bevacizumab
Drug Deep Dive: Cetuximab (Erbitux)
- Cetuximab (Erbitux): The Complete Patient Guide
- Cetuximab Infusion Day: Premedication, Duration and What to Expect
- Cetuximab Infusion Reactions: Why the First Dose Is Given Slowly
- Cetuximab Myths: 'The Worse the Rash, the Better' and Other Half-Truths
- Cetuximab Price in India: Innovator, Biosimilar and Cost Per Cycle
- Cetuximab Side Effects: The Complete List and Timeline
- Cetuximab Success Rate and Survival: An Honest Look at the Numbers
- Cetuximab With FOLFIRI, FOLFOX and Radiation
- Cetuximab in Colorectal vs Head and Neck Cancer: Different Roles
- Cetuximab in Elderly Patients and Those With Other Illnesses
- Cetuximab vs Bevacizumab in Colorectal Cancer: Which and When
- Diet and Nutrition While on Cetuximab
- Drug, Food and Supplement Interactions With Cetuximab
- Fertility, Pregnancy and Contraception on Cetuximab
- How Does Cetuximab Work? The Anti-EGFR Monoclonal Antibody Explained
- How Long Does Cetuximab Take to Work?
- How Long Will You Stay on Cetuximab?
- Low Magnesium on Cetuximab: Cramps, Fatigue and Monthly Testing
- Tests and Monitoring While You Are on Cetuximab
- The Cetuximab Rash: Severity, Treatment and Why It Predicts Response
- When Cetuximab Stops Working: Resistance and What Comes Next
- Who Is Eligible for Cetuximab? RAS Wild-Type Colorectal Cancer and Head and Neck Cancer
- Why Cetuximab Only Works in RAS Wild-Type, Left-Sided Tumours
- Will Insurance or a Government Scheme Pay for Cetuximab?
- Work, Travel and Daily Life on Cetuximab
Drug Deep Dive: Sorafenib (Nexavar)
- Blood Pressure, Rash and Hair Thinning on Sorafenib
- Diarrhoea on Sorafenib: Controlling It Without Stopping Treatment
- Diet and Nutrition While on Sorafenib
- Drug, Food and Supplement Interactions With Sorafenib
- Fertility, Pregnancy and Contraception on Sorafenib
- Hand-Foot Skin Reaction on Sorafenib: Prevention From Day One
- How Does Sorafenib Work? The Multi-Kinase Angiogenesis Inhibitor Explained
- How Long Does Sorafenib Take to Work?
- How Long Will You Stay on Sorafenib?
- Sorafenib (Nexavar, Soranib): The Complete Patient Guide
- Sorafenib Myths: Dose Reduction, 'Last Resort' and Generic Quality
- Sorafenib Price in India: Brand, Generic and Monthly Cost
- Sorafenib Side Effects: The Complete List and Timeline
- Sorafenib Success Rate and Survival: An Honest Look at the Numbers
- Sorafenib With Cirrhosis: Why Child-Pugh Status Decides Eligibility
- Sorafenib With TACE and Other Liver-Directed Treatments
- Sorafenib in Elderly Patients and Those With Other Illnesses
- Sorafenib in Liver, Kidney and Thyroid Cancer: Three Different Uses
- Sorafenib vs Lenvatinib for Liver Cancer: Cost, Tolerability and Evidence
- Taking Sorafenib: Food, Timing and What to Do If You Miss a Dose
- Tests and Monitoring While You Are on Sorafenib
- When Sorafenib Stops Working: Resistance and What Comes Next
- Who Is Eligible for Sorafenib? Liver, Kidney and Radioiodine-Refractory Thyroid Cancer
- Will Insurance or a Government Scheme Pay for Sorafenib?
- Work, Travel and Daily Life on Sorafenib
Next step
Still not sure what applies to you?
Send your reports across and a senior medical oncologist will go through what they mean, what is known, and what the options actually are.
Common questions
Frequently asked questions
Does lenvatinib stopping working mean the cancer cannot be treated further?
No. Progression on one treatment does not exhaust your options. For each of the cancers lenvatinib is used in, at least one established second-line treatment is recognised in NCCN and ESMO guidelines, and clinical trials may offer additional options. The question to focus on now is which next option fits your cancer type, your molecular profile, and your current fitness — and that is a question your oncologist can map out specifically for you.
How long does lenvatinib usually work before the cancer starts growing again?
This varies considerably between cancer types and between individuals. Clinical trial data published in support of NCCN and ESMO guidelines describes population-level outcomes, but those figures describe a group — not a prediction for any one person. Your own response may be shorter or longer than any reported median. The more useful question to ask your oncologist is how your current scan compares to what the evidence would expect for your specific cancer type and stage, and what signs of progression to watch for between appointments.
Is another biopsy worth doing after lenvatinib stops working?
Often yes. Tumours accumulate new changes as they adapt to treatment, and a biopsy at progression may reveal mutations or targets not present at your original diagnosis — some of which have approved treatments. A liquid biopsy from blood is sometimes sufficient and avoids a repeat procedure. Whether it is worth doing depends on your cancer type, your fitness, and whether the result is likely to change what your team recommends. Ask your oncologist directly whether retesting applies to your situation.
Can lenvatinib be restarted after stopping for a while?
This is occasionally considered in specific clinical situations, but it is not a standard approach across the cancers lenvatinib treats, and the evidence base for rechallenge is limited compared to established second-line options. If your oncologist suggests it, ask what the evidence says for your specific cancer type and how that compares to the alternatives. It is a reasonable question, and the answer will depend on your individual situation.
What if I am not fit enough for second-line treatment?
Not all second-line options are equally demanding. Some are less intensive than others, and the choice your team makes will take your current fitness into account. If you are not well enough for active second-line treatment, your oncologist may recommend a period of supportive care focused on managing symptoms and maintaining quality of life — which is a careful and appropriate medical decision. Ask what each option would involve day to day, and tell your team honestly what matters most to you at this point.
Are clinical trials for lenvatinib resistance available in India?
Yes. India participates in multinational trials and CTRI — the Clinical Trials Registry of India — lists actively recruiting studies. Your oncologist can check whether any currently open trial matches your cancer type and molecular profile. Raise this at your next appointment rather than searching on your own, because eligibility criteria are precise, and your team can identify trials that genuinely fit rather than ones that only appear to match on a broad description.